
Should You Buy Corxel US Before the SPAC Merger Closes?
Corxel US is a clinical-stage biopharmaceutical company developing oral obesity and cardiometabolic therapies, and it is going public through a merger with Amanat Acquisition Corp. (Nasdaq: AMAN). The deal is expected to close in the first half of 2027, but shareholders should watch the cash raise and redemption math closely because dilution and trust leakage could reshape the setup.
